The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial. Published reports were searched in PubMed, EMBASE, and Google Scholar. Twelve publications with 3903 patients had met the inclusion criteria and were subjected to further examination. We found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 − 0.75; p < 0.00001; I2 = 47%). WT1 rs16754 polymorphism was also significantly associated with RFS in AML (OR = 0.69; 95% CI 0.57 − 0.83; p < 0.001; I2 = 46%). In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.

[1]  A. Ho,et al.  Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation , 2016, International journal of cancer.

[2]  Ling-ling Wei,et al.  WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation , 2015, Molecular Diagnosis & Therapy.

[3]  Wei Zhang,et al.  Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. , 2015, Leukemia research.

[4]  M. Ladanyi,et al.  EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation. , 2014, Cancer research.

[5]  T. Misawa,et al.  Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer , 2014, Clinical Cancer Research.

[6]  Shenmeng Gao,et al.  Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia , 2014, Leukemia & lymphoma.

[7]  D. Tenen,et al.  Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. , 2013, Cancer cell.

[8]  P. Bolufer,et al.  Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients , 2012, Annals of Hematology.

[9]  K. Wagner,et al.  ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia , 2012, British journal of haematology.

[10]  Yunsuk Choi,et al.  Single nucleotide polymorphism of Wilms’ tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia , 2012, Annals of Hematology.

[11]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[12]  X Thomas,et al.  Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia , 2011, Leukemia.

[13]  M. Caligiuri,et al.  Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study , 2011, Haematologica.

[14]  Julia Kuhn,et al.  WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Pieters,et al.  No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Döhner,et al.  Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. V. D. van der Velden,et al.  Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  U. Maurer,et al.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. , 1997, Experimental hematology.

[20]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[21]  S. Horswell,et al.  The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia , 2015, Annals of Hematology.

[22]  J. Liao,et al.  Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia. , 2015, European review for medical and pharmacological sciences.

[23]  D. Beyer,et al.  WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors , 2015, Pathology & Oncology Research.